Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jean-Yves Douillard
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Salvatore Siena
Consultant or Advisory Role - Amgen; Bayer; Celgene; Genomic Health; Roche; Sanofi
Josep Tabernero
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; ImClone Systems; Lilly; Merck KGaA
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Ronald L. Burkes
Consultant or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Lilly; Sanofi
Honoraria - Amgen; Biogen Idec; Boehringer Ingelheim; Lilly; Roche; Sanofi
Mario Edmundo Barugel
Consultant or Advisory Role - Roche
Honoraria - Amgen; Roche
Yves Humblet
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Gyorgy Bodoky
Consultant or Advisory Role - Amgen
David Cunningham
Employment or Leadership Position - Royal Marsden NHS Foundation Trust
Research Funding - Amgen; Celgene; Merck Serono; Novartis; Roche; Sanofi
Jacek Jassem
No relevant relationships to disclose
Fernando Rivera
Research Funding - Amgen
Ilona Kocáková
No relevant relationships to disclose
Paul Ruff
Research Funding - Amgen
Other Remuneration - Amgen
Maria Blasinska-Morawiec
No relevant relationships to disclose
Martin Smakal
No relevant relationships to disclose
Richard Thomas Williams
No relevant relationships to disclose
Alan Rong
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jeffrey S. Wiezorek
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Roger Sidhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Scott D. Patterson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen